Epigenomic characterization of locally advanced anal cancer

A radiation therapy oncology group 98-11 specimen study

Erin M. Siegel, Steven Eschrich, Kathryn Winter, Bridget Riggs, Anders Berglund, Abidemi Ajidahun, Jeff Simko, Jennifer Moughan, Jaffer Ajani, Anthony Magliocco, Abul Elahi, Sarah Hoffe, David Shibata

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The Radiation Therapy Oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. Tumor size (>5 cm) and lymph node metastases are associated with disease progression. There may be key molecular differences (eg, DNA methylation changes) in tumors at high risk for progression. Objective: The objectives of this study were to determine whether there are differences in DNA methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. Design: This was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial. DNA methylation was measured using the Illumina HumanMethylation450 Array. Settings: The study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. Patients: The patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years). Main Outcome Measures: DNA methylation differences at individual CpG sites and within genes between low- and high-risk patients were compared using the Mann-Whitney test (p < 0.001). Results: A total of 16 CpG loci were differentially methylated (14 increased and 2 decreased) in high-versus low-risk cases. Genes harboring differentially methylated CpG sites included known tumor suppressor genes and novel targets. Limitations: This study only included patients in the mitomycin-C arm with tumor tissue; however, this sample was representative of the trial. Conclusions: This is the first study to apply genomewide methylation analysis to anal cancer. Biologically relevant differences in methylated targets were found to discriminate locally advanced from early anal cancer. Epigenetic events likely play a significant role in the progression of anal cancer and may serve as potential biomarkers.

Original languageEnglish (US)
Pages (from-to)941-957
Number of pages17
JournalDiseases of the Colon and Rectum
Volume57
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Anus Neoplasms
Radiation Oncology
Epigenomics
Radiotherapy
DNA Methylation
Mitomycin
Neoplasms
Fluorouracil
Clinical Trials
Genes
Background Radiation
Squamous Cell Neoplasms
Tumor Suppressor Genes
Tertiary Care Centers
Individuality
Methylation
Cisplatin
Disease Progression
Biomarkers
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Epigenomic characterization of locally advanced anal cancer : A radiation therapy oncology group 98-11 specimen study. / Siegel, Erin M.; Eschrich, Steven; Winter, Kathryn; Riggs, Bridget; Berglund, Anders; Ajidahun, Abidemi; Simko, Jeff; Moughan, Jennifer; Ajani, Jaffer; Magliocco, Anthony; Elahi, Abul; Hoffe, Sarah; Shibata, David.

In: Diseases of the Colon and Rectum, Vol. 57, No. 8, 01.01.2014, p. 941-957.

Research output: Contribution to journalArticle

Siegel, EM, Eschrich, S, Winter, K, Riggs, B, Berglund, A, Ajidahun, A, Simko, J, Moughan, J, Ajani, J, Magliocco, A, Elahi, A, Hoffe, S & Shibata, D 2014, 'Epigenomic characterization of locally advanced anal cancer: A radiation therapy oncology group 98-11 specimen study', Diseases of the Colon and Rectum, vol. 57, no. 8, pp. 941-957. https://doi.org/10.1097/DCR.0000000000000160
Siegel, Erin M. ; Eschrich, Steven ; Winter, Kathryn ; Riggs, Bridget ; Berglund, Anders ; Ajidahun, Abidemi ; Simko, Jeff ; Moughan, Jennifer ; Ajani, Jaffer ; Magliocco, Anthony ; Elahi, Abul ; Hoffe, Sarah ; Shibata, David. / Epigenomic characterization of locally advanced anal cancer : A radiation therapy oncology group 98-11 specimen study. In: Diseases of the Colon and Rectum. 2014 ; Vol. 57, No. 8. pp. 941-957.
@article{e78f4060163a4fcdb88006f50f1163f8,
title = "Epigenomic characterization of locally advanced anal cancer: A radiation therapy oncology group 98-11 specimen study",
abstract = "Background: The Radiation Therapy Oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. Tumor size (>5 cm) and lymph node metastases are associated with disease progression. There may be key molecular differences (eg, DNA methylation changes) in tumors at high risk for progression. Objective: The objectives of this study were to determine whether there are differences in DNA methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. Design: This was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial. DNA methylation was measured using the Illumina HumanMethylation450 Array. Settings: The study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. Patients: The patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years). Main Outcome Measures: DNA methylation differences at individual CpG sites and within genes between low- and high-risk patients were compared using the Mann-Whitney test (p < 0.001). Results: A total of 16 CpG loci were differentially methylated (14 increased and 2 decreased) in high-versus low-risk cases. Genes harboring differentially methylated CpG sites included known tumor suppressor genes and novel targets. Limitations: This study only included patients in the mitomycin-C arm with tumor tissue; however, this sample was representative of the trial. Conclusions: This is the first study to apply genomewide methylation analysis to anal cancer. Biologically relevant differences in methylated targets were found to discriminate locally advanced from early anal cancer. Epigenetic events likely play a significant role in the progression of anal cancer and may serve as potential biomarkers.",
author = "Siegel, {Erin M.} and Steven Eschrich and Kathryn Winter and Bridget Riggs and Anders Berglund and Abidemi Ajidahun and Jeff Simko and Jennifer Moughan and Jaffer Ajani and Anthony Magliocco and Abul Elahi and Sarah Hoffe and David Shibata",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/DCR.0000000000000160",
language = "English (US)",
volume = "57",
pages = "941--957",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Epigenomic characterization of locally advanced anal cancer

T2 - A radiation therapy oncology group 98-11 specimen study

AU - Siegel, Erin M.

AU - Eschrich, Steven

AU - Winter, Kathryn

AU - Riggs, Bridget

AU - Berglund, Anders

AU - Ajidahun, Abidemi

AU - Simko, Jeff

AU - Moughan, Jennifer

AU - Ajani, Jaffer

AU - Magliocco, Anthony

AU - Elahi, Abul

AU - Hoffe, Sarah

AU - Shibata, David

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The Radiation Therapy Oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. Tumor size (>5 cm) and lymph node metastases are associated with disease progression. There may be key molecular differences (eg, DNA methylation changes) in tumors at high risk for progression. Objective: The objectives of this study were to determine whether there are differences in DNA methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. Design: This was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial. DNA methylation was measured using the Illumina HumanMethylation450 Array. Settings: The study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. Patients: The patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years). Main Outcome Measures: DNA methylation differences at individual CpG sites and within genes between low- and high-risk patients were compared using the Mann-Whitney test (p < 0.001). Results: A total of 16 CpG loci were differentially methylated (14 increased and 2 decreased) in high-versus low-risk cases. Genes harboring differentially methylated CpG sites included known tumor suppressor genes and novel targets. Limitations: This study only included patients in the mitomycin-C arm with tumor tissue; however, this sample was representative of the trial. Conclusions: This is the first study to apply genomewide methylation analysis to anal cancer. Biologically relevant differences in methylated targets were found to discriminate locally advanced from early anal cancer. Epigenetic events likely play a significant role in the progression of anal cancer and may serve as potential biomarkers.

AB - Background: The Radiation Therapy Oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. Tumor size (>5 cm) and lymph node metastases are associated with disease progression. There may be key molecular differences (eg, DNA methylation changes) in tumors at high risk for progression. Objective: The objectives of this study were to determine whether there are differences in DNA methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. Design: This was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial. DNA methylation was measured using the Illumina HumanMethylation450 Array. Settings: The study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. Patients: The patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years). Main Outcome Measures: DNA methylation differences at individual CpG sites and within genes between low- and high-risk patients were compared using the Mann-Whitney test (p < 0.001). Results: A total of 16 CpG loci were differentially methylated (14 increased and 2 decreased) in high-versus low-risk cases. Genes harboring differentially methylated CpG sites included known tumor suppressor genes and novel targets. Limitations: This study only included patients in the mitomycin-C arm with tumor tissue; however, this sample was representative of the trial. Conclusions: This is the first study to apply genomewide methylation analysis to anal cancer. Biologically relevant differences in methylated targets were found to discriminate locally advanced from early anal cancer. Epigenetic events likely play a significant role in the progression of anal cancer and may serve as potential biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84904861330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904861330&partnerID=8YFLogxK

U2 - 10.1097/DCR.0000000000000160

DO - 10.1097/DCR.0000000000000160

M3 - Article

VL - 57

SP - 941

EP - 957

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 8

ER -